Roche and Hansoh Pharma announced a strategic licensing collaboration covering multiple antibody-drug conjugate programs.
Hansoh will receive $400 million upfront, $110 million on the first anniversary, and eligibility for more than $15 billion in contingent development, regulatory, and commercial milestones, plus tiered royalties.
The collaboration includes two existing Hansoh preclinical ADC programs and additional programs based on Roche-nominated targets. Hansoh will lead early development through global Phase Ia trials, after which Roche will lead development outside Greater China; Hansoh also retains an option to participate in the development of up to two programs outside those markets. Hansoh Pharmaceutical
Primary source: Hansoh official announcement, October 19
Why it matters strategically
The headline value requires careful interpretation.
More than $15 billion in potential milestones is not equivalent to $15 billion in committed capital.
The immediately identified payment structure consists of $400 million upfront and $110 million after one year.
The remaining payments depend on future events across multiple development programs.
This distinction matters because a multi-asset licensing agreement can generate an extremely large theoretical transaction value without requiring the licensee to commit that amount immediately.
The arrangement also divides development responsibilities across stages.
Hansoh retains responsibility for early development.
Roche assumes subsequent global development and commercialization obligations outside Greater China.
